Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus

NCT02036372 · Completed

Last updated 2026-05-28

This clinical trial is testing different treatments (insulin, GIK, or GLP-1) to manage blood sugar levels during surgery in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 150 people

Who can join Ages 18–75 · all sexes

Timeline Started 2014-01 · est. completion 2017-01

Where 3 sites · Netherlands

What this study is testing ClinicalTrials.gov NCT02036372 ↗

Description as written by the study sponsor.

The incidence of diabetes mellitus type II is increasing. More and more patients who need surgery have diabetes mellitus type II. Despite an enormous amount of glucose lowering protocols and the proven negative effects of hyperglycaemia. There is no evidence for the optimal glucose lowering protocol. This study investigates the optimal intraoperative treatment algorithm to lower glucose in patients with diabetes mellitus type 2 undergoing non-cardiac surgery, comparing intraoperative glucose-insulin-potassium infusion (GIK), insulin bolus regimen (BR) and GLP-1 (liraglutide, LG) treatment.

Treatments tested

Liraglutide also known as Victoza Drug
Insulin bolus also known as novorapid Drug
GIK infusion also known as glucose, insulin, potassium infusion Drug

continuous infusion

Main thing measured	Median glucose
Sponsor	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Conditions studied	Diabetes Mellitus Type II
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02036372 ↗